Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)

被引：0
|
作者：
James Amamoo [1 ]
Riddhi Doshi [2 ]
Joshua Noone [1 ]
Lin Xie [1 ]
Cory Gamble [1 ]
Mico Guevarra [1 ]
Victoria Divino [2 ]
Justin Chen [2 ]
Aaron King [3 ]
机构：
[1] Novo Nordisk Inc.,
[2] IQVIA,undefined
[3] MedFirst Primary Care – Quarry,undefined
来源：
Diabetes Therapy | 2025年 / 16卷 / 5期
关键词：
BMI; GLP-1 receptor agonist; HbA1c; Healthcare resource utilization; Real-world evidence; Semaglutide; SGLT2i; Type 2 diabetes; Weight;
D O I：
10.1007/s13300-025-01721-y
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1033 / 1048
页数：15
相关论文
共 50 条
  • [1] Real-World Impact of Once-Weekly Injectable Semaglutide on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes-An Observational Study (PAUSE)
    Amamoo, James
    Doshi, Riddhi P.
    Noone, Joshua
    Xie, Lin
    Gamble, Cory L.
    Guevarra, Mico
    Divino, Victoria
    Chen, Justin
    King, Aaron A.
    DIABETES, 2024, 73
  • [2] Real-World Impact of Once-Weekly Injectable Semaglutide (sema OW) vs. Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) on HbA1c, Weight, and Health Care Resource Utilization (HCRU) Outcomes in Type 2 Diabetes (T2D)-An Observational Study (PAUSE)
    Amamoo, James
    Doshi, Riddhi P.
    Noone, Joshua
    Xie, Lin
    Gamble, Cory L.
    Guevarra, Mico
    Divino, Victoria
    Chen, Justin
    King, Aaron A.
    DIABETES, 2024, 73
  • [3] Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 mg Weekly Dose of Once-Weekly Semaglutide for Diabetes
    Gronroos, Noelle N.
    Swift, Caroline
    Frazer, Monica S.
    Sargent, Andrew
    Leszko, Michael
    Buysman, Erin
    Alvarez, Sara
    Dunn, Tyler J.
    Noone, Josh
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2024, 11 (02): : 118 - 124
  • [4] The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes
    Whalen, Karen
    Miller, Shannon
    St Onge, Erin
    CLINICAL THERAPEUTICS, 2015, 37 (06) : 1150 - 1166
  • [5] Investigating effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes in Scotland: A real-world observational pharmacoepidemiology study
    Caparrotta, T. M.
    Blackbourn, L. A. K.
    Colhoun, H. M.
    McKeigue, P. M.
    McGurnaghan, S. J.
    DIABETIC MEDICINE, 2023, 40
  • [6] Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
    Menzen, Markus
    Berentzen, Tina Landsvig
    Catarig, Andrei-Mircea
    Pieperhoff, Sebastian
    Simon, Joerg
    Jacob, Stephan
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2023, 131 (04) : 205 - 215
  • [7] Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes
    Mikhail, Nasser
    WORLD JOURNAL OF DIABETES, 2014, 5 (06): : 854 - 859
  • [8] Real-World Impact of Once-Weekly Injectable Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE-OW Injectable Semaglutide)
    Amamoo, James
    Doshi, Riddhi P.
    Noone, Joshua
    Tan, Xi
    Xie, Lin
    Gamble, Cory L.
    Guevarra, Mico
    Chen, Justin
    King, Aaron A.
    DIABETES, 2023, 72
  • [9] Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes
    Frazer, Monica
    Swift, Caroline
    Sargent, Andrew
    Leszko, Michael
    Buysman, Erin
    Gronroos, Noelle N.
    Alvarez, Sara
    Dunn, Tyler J.
    Noone, Josh
    Gamble, Cory L.
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2024, 23 (01) : 783 - 788
  • [10] Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease
    Hunsuwan, Supattra
    Boongird, Sarinya
    Ingsathit, Atiporn
    Ponthongmak, Wanchana
    Unwanatham, Nattawut
    Mckay, Gareth J.
    Attia, John
    Thakkinstian, Ammarin
    SCIENTIFIC REPORTS, 2025, 15 (01):
12345